PHARMING GRP SP. ADRS Asset Resilience Ratio
PHARMING GRP SP. ADRS asset resilience ratio. PHARMING GRP SP. ADRS (PHG) has an Asset Resilience Ratio of 6.76% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See defensive interval ratio of PHARMING GRP SP. ADRS to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of PHARMING GRP SP. ADRS (2022–2025)
Asset resilience ratio of PHARMING GRP SP. ADRS from 2022 to 2025. This chart shows how PHARMING GRP SP. ADRS's Asset Resilience Ratio has changed over time. Read PHG liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down PHARMING GRP SP. ADRS's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is PHARMING GRP SP. ADRS's balance sheet.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €33.80 Million | 6.76% |
| Total Liquid Assets | €33.80 Million | 6.76% |
Asset Resilience Insights
- Limited Liquidity: PHARMING GRP SP. ADRS maintains only 6.76% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
PHARMING GRP SP. ADRS Industry Peers by Asset Resilience Ratio
Compare PHARMING GRP SP. ADRS's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
PHARMING GRP SP. ADRS Asset Resilience Ratio by Year (2022–2025)
PHARMING GRP SP. ADRS asset resilience ratio by year from 2022 to 2025. The table below shows the annual Asset Resilience Ratio data for PHARMING GRP SP. ADRS.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 6.76% | €33.80 Million ≈ $39.51 Million |
€499.96 Million ≈ $584.51 Million |
-21.48pp |
| 2024-12-31 | 28.24% | €112.95 Million ≈ $132.05 Million |
€399.99 Million ≈ $467.62 Million |
-4.53pp |
| 2023-12-31 | 32.77% | €151.68 Million ≈ $177.33 Million |
€462.85 Million ≈ $541.12 Million |
-- |
| 2022-12-31 | 0.00% | €0.00 ≈ $0.00 |
€425.80 Million ≈ $497.80 Million |
-- |
About PHARMING GRP SP. ADRS
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE… Read more